2. NF-κB Immunology/Inflammation
  3. NF-κB SOD
  4. Bartogenic acid

Bartogenic acid is an orally active NF-κB inhibitor, found in Barringtonia racemosa fruits. Bartogenic acid increases catalase, superoxide dismutase (SOD), and glutathione levels. Bartogenic acid inhibits lipid peroxidation and suppresses inflammation markers. Bartogenic acid can be used for the research of ovarian cancer, skin cancer, and inflammatory conditions.

For research use only. We do not sell to patients.

Bartogenic acid

Bartogenic acid Chemical Structure

CAS No. : 79355-89-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Bartogenic acid Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bartogenic acid is an orally active NF-κB inhibitor, found in Barringtonia racemosa fruits. Bartogenic acid increases catalase, superoxide dismutase (SOD), and glutathione levels. Bartogenic acid inhibits lipid peroxidation and suppresses inflammation markers. Bartogenic acid can be used for the research of ovarian cancer, skin cancer, and inflammatory conditions[1][2][3][4].

IC50 & Target[1]

NF-κB

 

In Vitro

Bartogenic acid (0.1-100 μM; 48 h) inhibits the growth of human ovarian cancer SKOV-3 cells in vitro with an IC50 of 15.72 μM[1].
Bartogenic acid (48 h) potently and selectively induces cytotoxicity in human skin carcinoma SCC-13 cells (IC50=7.5 µM) with a selectivity index of 4.05[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bartogenic acid Related Antibodies

Cell Viability Assay[1]

Cell Line: human ovarian cancer SKOV-3 cells
Concentration: 0.1 μM; 1 μM; 10 μM; 50 μM; 100 μM
Incubation Time: 48 h
Result: Dose-dependently reduced the viability of SKOV-3 cells, with an IC50 value of 15.72 μM after 48 h of treatment.
Decreased as the concentration of bartogenic acid increased.
In Vivo

Bartogenic acid (3 mg/kg; i.v.; daily; 21 days) reduces SKOV-3 ovarian tumor growth by 41.47% in SCID mice[1].
Bartogenic acid (1-4 mg/kg; p.o./topical; daily; 13.5 weeks) exhibits dose-dependent chemopreventive efficacy against DMBA (HY-W011845)/Croton oil-induced skin cancer in Swiss albino mice, with the 4 mg/kg oral dose achieving the lowest tumor incidence (36.1%) and near-normal antioxidant marker levels and skin architecture[2].
Bartogenic acid (2-10 mg/kg; p.o.; daily for 21 days) protects rats against the primary and secondary arthritic lesions, body weight changes and haematological perturbations induced by CFA (HY-153808)[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID (female, 5 weeks old, subcutaneous inoculation of SKOV-3 cells to establish a xenograft model)[1]
Dosage: 3 mg/kg
Administration: i.v.; daily; 21 days
Result: Achieved 41.47% tumor growth inhibition (p < 0.001) compared to vehicle controls, with mean tumor volume of 364.70 mm3 on day 21.
Showed no significant reduction in NF-κB H score, viable tumor cell score, fibrosis score, TGF-β1 levels, or MMP9 levels, but significantly increased necrosis score (p < 0.05).
Animal Model: Swiss albino (6-8 weeks old, 23-25 gm, DMBA/Croton oil-induced two-stage skin carcinogenesis)[2]
Dosage: 1 mg/kg; 2 mg/kg; 4 mg/kg
Administration: p.o.; daily; 13.5 weeks; topical; daily; 13.5 weeks
Result: Reduced tumor incidence to 89.3%, with an average of 9.72 tumors per tumor-bearing mouse, mean tumor volume of 124.8 mm3, and mean tumor weight of 1.01 gm at 1 mg/kg oral dose.
Partially restored glutathione (GSH) content and activities of catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSHPx), with mild histopathological improvement at 1 mg/kg oral dose.
Reduced tumor incidence to 52.4%, with an average of 6.34 tumors per tumor-bearing mouse, mean tumor volume of 89.7 mm3, and mean tumor weight of 0.61 gm at 2 mg/kg oral dose.
Significantly reduced skin malondialdehyde (MDA) levels to 125.7 μg/mg protein, restored GSH content to near-normal levels, significantly increased catalase, SOD, and GSHPx activities, and preserved normal skin architecture with only mild epidermal cell invasion at 2 mg/kg oral dose.
Reduced tumor incidence to 36.1%, with an average of 4.19 tumors per tumor-bearing mouse, mean tumor volume of 45.6 mm3, and mean tumor weight of 0.11 gm at 4 mg/kg oral dose.
Significantly reduced skin MDA levels to 104.5 μg/mg protein, restored GSH content and catalase, SOD, and GSHPx activities to near-normal levels, and preserved fully normal skin architecture with no epidermal thickening or cell invasion at 4 mg/kg oral dose.
Reduced tumor incidence to 48.2%, with an average of 8.21 tumors per tumor-bearing mouse, mean tumor volume of 63.5 mm3, and mean tumor weight of 0.51 gm at 4 mg/kg topical dose.
Reduced skin MDA levels to 141.6 μg/mg protein, restored GSH content and catalase, SOD, and GSHPx activities to near-normal levels, and showed mild to moderate histopathological improvement at 4 mg/kg topical dose.
Animal Model: Wistar rats (either sex, 100-150 g, Complete Freund’s Adjuvant-induced arthritis)[3]
Dosage: 2 mg/kg; 5 mg/kg; 10 mg/kg
Administration: p.o.; daily; 21 days
Result: Reduced primary arthritic lesions to 113% rise in injected paw volume and secondary lesions to 15% rise in non-injected paw volume at 2 mg/kg, 109% rise and 12% rise at 5 mg/kg, and 91% rise and 11% rise at 10 mg/kg (all P < .01).
Resulted in 37 g body weight gain at 2 mg/kg, 36 g gain at 5 mg/kg, and 39 g gain at 10 mg/kg (all P < .01).
Reduced thymus weight to 0.12 g and spleen weight to 0.96 g at 2 mg/kg, 0.12 g and 0.84 g at 5 mg/kg, and 0.085 g and 0.74 g at 10 mg/kg (all thymus weights and 5 mg/kg, 10 mg/kg spleen weights P < .05 or P < .01).
Reduced WBC count to 7.5 ×103/mm3, ESR to 12 mm/h, CRP to 4.4 mg/dL, and RF to 37 IU/mL at 2 mg/kg; increased RBC count to 9 ×106/mm3, reduced WBC count to 7.2 ×103/mm3, increased Hb to 15 mg%, reduced CRP to 2.2 mg/dL, and RF to 33 IU/mL at 5 mg/kg; increased RBC count to 9.8 ×106/mm3, reduced WBC count to 5.6 ×103/mm3, reduced ESR to 11 mm/h, increased Hb to 16 mg%, reduced CRP to 1.4 mg/dL, and RF to 23 IU/mL at 10 mg/kg (all significant vs control, P < .01).
Reduced arthritis score to median 6 (4, 8), flexion pain test score to median 1.5 (1, 2), mobility score to median 1.5 (1, 2), and improved stance score to median 3 (2, 3) at 10 mg/kg (P < .05 or P < .01); 2 mg/kg and 5 mg/kg showed non-significant pain score improvements.
Protected against soft tissue swelling, periarticular bone resorption, bone erosion, and joint space narrowing in the adjuvant-injected paw at 10 mg/kg.
Molecular Weight

518.68

Formula

C30H46O7
CAS No.
SMILES

OC([C@]12[C@]([C@@H](C(C)(CC2)C)O)([H])C3=CC[C@@]([C@@]4([C@@]([C@](C)([C@H]([C@@H](C4)O)O)C(O)=O)([H])CC5)C)([H])[C@]5(C)[C@@]3(CC1)C)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bartogenic acid Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bartogenic acid79355-89-8NF-κBSODNuclear factor-κBNuclear factor-kappaBSuperoxide Dismutasehuman skin carcinoma SCC-13 cellsSCID miceovarian cancer cellshuman PBMCadjuvant-induced arthritisBarringtonia racemosahuman ovarian cancer SKOV-3 cellsSwiss albino miceskin carcinoma cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bartogenic acid
Cat. No.:
HY-N19717
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.